Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inner-City Anti-IgE Therapy for Asthma (ICAC-08)

Trial Profile

Inner-City Anti-IgE Therapy for Asthma (ICAC-08)

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Acronyms ICATA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Mar 2018 Results of post hoc analysis assessing the effect of asthma severity on treatment outcomes with Omalizumab presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 22 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top